PARDES BIOSCIENCES, INC.

FS Development Corp. II, trading under ticker FSII, is a blank-check company sponsored by FS Development Holdings II, LLC, an affiliate of healthcare-focused investment firm Foresite Capital. The SPAC completed its initial public offering in June 2021 and filed an 8-K on June 29, 2021 in connection with that closing, targeting the biopharmaceutical and life sciences sector. FSII subsequently entered into a business combination with Pardes Biosciences, Inc., a clinical-stage company developing oral antiviral therapies, with the transaction closing in early 2022. Pardes Biosciences later wound down its operations after discontinuing its lead antiviral program. Sign up on SpacDesk for full filing histories, sponsor profiles, and deal timelines across the SPAC universe.